From: Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies
 | Measured parameters | Model parameters | ||
---|---|---|---|---|
 | Value | Unit | Value | Unit |
VEGFR1 | Â | Â | Â | Â |
   Luminal EC (normal) | 550 | rec/EC | 1.21 × 10-1 | pmol/cm3 tissue |
   Abluminal EC (normal) | 550 | rec/EC | 9.86 × 10-3 | pmol/cm3 tissue |
   Luminal EC (diseased) | 3,750 | rec/EC | 4.38 × 10-4 | pmol/cm3 tissue |
   Abluminal EC (diseased) | 3,750 | rec/EC | 6.54 × 10-2 | pmol/cm3 tissue |
   Myocytes | 0 | rec/myocyte | 0 | pmol/cm3 tissue |
   Tumor cells | 1,100 | rec/tumor cell | 2.81 × 10-1 | pmol/cm3 tissue |
VEGFR2 | Â | Â | Â | Â |
   Luminal EC (normal) | 350 | rec/EC | 7.70 × 10-2 | pmol/cm3 tissue |
   Abluminal EC (normal) | 350 | rec/EC | 6.28 × 10-3 | pmol/cm3 tissue |
   Luminal EC (diseased) | 300 | rec/EC | 3.51 × 10-5 | pmol/cm3 tissue |
   Abluminal EC (diseased) | 300 | rec/EC | 5.23 × 10-3 | pmol/cm3 tissue |
   Myocytes | 0 | rec/myocyte | 0 | pmol/cm3 tissue |
   Tumor cells | 550 | rec/tumor cell | 1.41 × 10-1 | pmol/cm3 tissue |
NRP1 | Â | Â | Â | Â |
   Luminal EC (normal) | 17,500 | rec/EC | 3.74 | pmol/cm3 tissue |
   Abluminal EC (normal) | 17,500 | rec/EC | 3.05 × 10-1 | pmol/cm3 tissue |
   Luminal EC (diseased) | 20,000†| rec/EC | 2.34 × 10-3 | pmol/cm3 tissue |
   Abluminal EC (diseased) | 20,000†| rec/EC | 3.49 × 10-1 | pmol/cm3 tissue |
   Myocytes | 34,500 | rec/myocyte | 2.06 | pmol/cm3 tissue |
   Tumor cells | 39,500 | rec/tumor cell | 1.01 × 101 | pmol/cm3 tissue |
NRP2 | Â | Â | Â | Â |
   Luminal EC (normal) | 0 | rec/EC | 0 | pmol/cm3 tissue |
   Abluminal EC (normal) | 0 | rec/EC | 0 | pmol/cm3 tissue |
   Luminal EC (diseased) | 0 | rec/EC | 0 | pmol/cm3 tissue |
   Abluminal EC (diseased) | 0 | rec/EC | 0 | pmol/cm3 tissue |
   Myocytes | 0 | rec/myocyte | 0 | pmol/cm3 tissue |
   Tumor cells | 39,500‡ | rec/tumor cell | 1.02 × 101 | pmol/cm3 tissue |